

S352
24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
syndrome ago. It has a history of cannabis, cocaine and alcohol since
he was thirteen and remains abstinent for more than six months
ago. Differential diagnosis arises between amotivational toxic syn-
drome, reactive depressive symptoms to the disease and negative
symptoms for chronic psychotic process. Finally diagnosed with
paranoid schizophrenia and is included in the program of first psy-
chotic episodes.
Today the productive symptoms disappeared and remain negative
though with less intensity achieving an improvement in overall
activity.
Conclusions
Consumption of toxic influences the development of
a chronic psychotic process that may appear years later, becom-
ing a etiological and maintainer factor, not only if its consumption
continue, but other effects that occur long term amotivational syn-
drome and worsening prognosis.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
Further readings
Luca, et al. Negative dimension in psychiatry. Amotivational syn-
drome as a paradigm of negative symptoms in substance abuse.
Simon Zhornitsky, et al. Research article psychopathology in
patients with substance use disorder and substance-induced with-
out psychosis. J Addict 2015.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.994EV10
Cannabis and cyclical vomiting
M. Canseco Navarro
∗
, M. Canccino Botello ,
M.M. Machado Vera , J.M. Hernández Sánchez , F. Molina López
Consorcio Hospital General Universitario, Conselleria de Sanitat,
Valencia, Spain
∗
Corresponding author.
Introduction
Traditionally,
cannabis is associated with
antiemetic action after acute consumption. However, in 2004
the cannabinoid hyperemesis as paradoxical effect of chronic
users, after years of exposure described.
Objectives
Description of the cannabinoid hyperemesis.
Method
OLOGYA case is presented.
Results
Clinical case of a woman who repeatedly comes to the
emergency service because of abdominal, nausea and vomiting
pain.
This is cyclical and hardly controllable. The gastroenterology ser-
vice studied in depth with negative results. She was followed up by
mental health borderline personality disorder and she consumed
cannabis at an early age, 20–30 joints daily.
When she reaches abstinence in short periods, ceases digestive dis-
comfort. However, aprece digestive symptoms with each relapse.
The present case showed improvement with cessation of cannabis
so it probably was the cannabinoid hyperemesis syndrome.
Conclusions
The cannabinoid hyperemesis is characterized by
recurrent episodes of nausea, vomiting, abdominal pain, and
chronic cannabis use. Temporary relief is achieved with hot baths.
Ceases when abstinence is achieved. It is a clinical entity that does
not have much information and requires further study.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
Further readings
Sullivan S. Cannabinoid hyperemesis. Can J Gastroenterol
2010;24(5):284–5.
Enriqueta Ochoa-Mangado, Gimenez Monica Jimenez, Salvador
Vadillo, Augustine Star Madoz-Gurpide. Vomitos side to cannabis
cyclic. Gastroenterol Hepatol 2009;32(6):406–9.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.995EV11
Clinical features of kinesthetic
hallucinations in cocaine-dependent
patients
C. Roncero
1 , 2 ,∗
, L. Rodriguez-Cintas
1 , 2, L. Grau-López
1 , 2,
E. Ros-Cucurull
2, J. Perez-Pazos
1, C. Barral
1 , 2, F. Palma-Alvarez
1,
V. Barrau
1, A. Herrrero-Fernandez
1, N. Vela
1, D. Romero
1,
M. Sorribes
1, M. Casas
2 , 3, A. Egido
1, J. Alvaros
1, C. Daigre
1 , 41
Vall d’Hebron University Hospital, Adddiction and Dual Diagnosis
Unit. Psychiatry, Barcelona, Spain
2
Universidad Autonoma de Barcelona, Psychiatry, Barcelona, Spain
3
Vall d’Hebron University Hospital, Psychiatry, Barcelona, Spain
4
Vall Hebron Institut Reserca, Addiction, Barcelona, Spain
∗
Corresponding author.
Introduction
Legal and illegal drugs can cause psychotic symp-
toms, in cocaine-dependent patients the prevalence of these
symptoms may reach 86% (Vorspan, 2012). It is estimated that
13–32% of cocaine-dependent patients have kinaesthetic halluci-
nations (Siegel, 1978; Mahoney, 2008; Roncero, 2012).
Objectives
To compare the prevalence of substance-induced psy-
chotic symptoms and compare the use of welfare/social resources
and social adjustment among cocaine-dependent patients (CD) and
other substances dependences (OtherD).
Methods
Two hundred and six patients seeking treatment at
the Addictions and Dual Diagnosis Unit of the Vall d’Hebron.
Patients were assessed by ad hoc questionnaire designed to collect
demographic data and psychotic symptoms associated with con-
sumption, a record of the care/social resources used by the patient
and the scale of social adaptation (SASS). A descriptive and bivariate
analysis of the data was performed.
Results
CD were 47.1% vs. 52.9% OtherD (66.1% alcohol, 17.4%
cannabis, 8.3% opioid, 8.3% benzodiazepines/other drugs). Of
cocaine dependent-patients, 65.6% present psychotic symptoms vs.
32.1% for the OtherD. Different exhibiting psychotic symptoms are:
self-referential (69.7% vs. 30.7%), delusions of persecution (43.4%
vs. 12.2%), hallucinations (49.4% vs. 14.3%), auditory hallucinations
(43.5% vs. 11.4%), visual hallucinations (30.4% vs. 5.7%) and kinaes-
thetic hallucinations (7.2% vs. 2.9%).
Cocaine-dependent patients significantly use more health care
resources in reference addiction unit (76.3% vs. 62.4%,
P
:.035)
and infectious diseases (22.7% vs. 5.5%,
P
:.000) and justice-related
(50.5% vs. 26 resources 0.6%;
P
:1.001) and less resources andmental
health (25.8% vs. 43.1%;
P
:.013).
Regarding social adaptation, no differences were found in the SASS.
Kinaesthetic hallucinations do not appear to be related to a greater
use of resources and in social adaptation.
References not available.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.996EV12
Risk factors for accidents among
cocaine-dependent patient seeking
treatment
C. Roncero
1 , 2 ,∗
, L. Rodriguez-Cintas
1 , 2, C. Daigre
1, J. Alvarez
3,
C. Barral
2, A. Abad
1, V. Nina
1, A. Herrero-Fernandez
1,
L. Grau-López
1 , 2, C. Barral
1 , 2, J. Pérez-Pazos
1,
E. Ros-Cucurrull
1 , 2, L. Rodriguez-Martos
1, M. Casas
3 , 41
Vall d’Hebron University Hospital, Addiction and Dual Diagnosis
Unit, Psychiatry, Barcelona, Spain
2
Universidad Autonoma de Barcelona, Psychiatry, Barcelona, Spain
3
Facultad de Medicina, Pharmacology, Valladolid, Spain
4
Vall d’Hebron University Hospital, Psychiatry, Barcelona, Spain
∗
Corresponding author.